Ir para o conteúdo principal

Grafa News and Videos — Page 1051

Destaques de Grafa

Grafa

Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial

Clearmind Medicine (NASDAQ:CMND), a clinical-stage pharmaceutical company focused on developing novel psychedelic-derived therapies, announced today that its lead candidate, CMND-100, has successfully met the primary safety and tolerability endpoints in its Phase I/IIa clinical trial.

Leia mais: Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial
Grafa

Genprex preclinical data shows Reqorsa overcoming resistance in lung cancer

Genprex (NASDAQ:GNPX), a clinical-stage gene therapy company, announced today that its collaborators presented compelling preclinical data for its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), at the American Association for Cancer Research (AACR) Annual Meeting 2026.

Leia mais: Genprex preclinical data shows Reqorsa overcoming resistance in lung cancer
Grafa
Industrials

Stanley Black & Decker affirms 2026 outlook following Section 232 tariff updates

Stanley Black & Decker (NYSE:SWK) announced today that recent adjustments to the Section 232 tariff regime—the federal trade policy governing aluminum and steel imports—are not expected to have a material impact on the company’s full-year 2026 financial guidance.

Leia mais: Stanley Black & Decker affirms 2026 outlook following Section 232 tariff updates

GARANTA JÁ SEU GRAFA EDGE

Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas